NeuroSense Therapeutics Ltd. filed a proxy statement for a special shareholder meeting on August 26, 2026, seeking authorization to effect one or more reverse stock splits at an aggregate ratio between 1-for-4 and 1-for-40. The Board will determine the exact ratio and effective date within 12 months if approved. This proposal addresses Nasdaq listing compliance issues regarding minimum bid price and market value requirements, with a grace period ending September 29, 2026. Failure to regain compliance could result in delisting from the Nasdaq Capital Market. The company operates in the biotechnology industry, focusing on developing therapies for neurological disorders.

NeuroSense Therapeutics Ltd. entered into Amendment No. 1 to its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating references from a prior Form F-3 registration statement to a new one declared effective by the SEC on July 31, 2026. This amendment allows the company to offer and sell ordinary shares with an aggregate offering price of up to $3,789,822 under the existing agreement. As of the filing date, NeuroSense had sold 6,762,825 ordinary shares for net proceeds of approximately $6.7 million. The Sales Agreement remains in full force and effect except as amended. NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of therapeutic treatments.

NeuroSense Therapeutics intends to file a New Drug Submission (NDS) to Health Canada for PrimeC to treat amyotrophic lateral sclerosis (ALS). The decision follows a constructive Pre-NDS meeting with Health Canada and is supported by Phase 2b PARADIGM clinical program data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037) and achievement of the primary TDP-43 biomarker endpoint (p=0.0421). NeuroSense is a biotechnology company developing disease-modifying treatments for neurodegenerative diseases.